For the quarter ended June 2026, Danaher (DHR) reported revenue of $6.27 billion, up 5.5% over the same period last year. EPS came in at $1.94, compared to $1.80 in the year-ago quarter.
The reported revenue represents a surprise of +2.88% over the Zacks Consensus Estimate of $6.09 billion. With the consensus EPS estimate being $1.84, the EPS surprise was +5.44%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total Growth - Organic sales (Core): 3% compared to the 1.9% average estimate based on five analysts. Total Sales- Diagnostics: $2.47 billion versus $2.33 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.8% change. Total Sales- Life Sciences: $1.88 billion versus the four-analyst average estimate of $1.79 billion. The reported number represents a year-over-year change of +5.7%. Total Sales- Biotechnology: $1.92 billion versus the four-analyst average estimate of $1.95 billion. The reported number represents a year-over-year change of +3.8%. Operating profit- Life Sciences: $244 million compared to the $228.43 million average estimate based on three analysts. Operating profit- Biotechnology: $556 million versus $574.6 million estimated by three analysts on average. Operating profit- Other: $-89 million compared to the $-88.96 million average estimate based on three analysts. Operating profit- Diagnostics: $416 million compared to the $521.81 million average estimate based on three analysts.View all Key Company Metrics for Danaher here>>>
Shares of Danaher have returned +12.9% over the past month versus the Zacks S&P 500 composite's -0.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Danaher Corporation (DHR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).